Tokyo-based deep-tech startup Mitate Zepto Technica (MZT) has officially joined a major national research initiative focused on next-generation semiconductors. The company will serve as the commercialization partner for a project aimed at advancing edge AI, leveraging its proprietary genome-analysis accelerator, RASEN. This strategic partnership with leading academic institutions marks a significant step toward translating cutting-edge research into practical, high-speed genomic solutions.
A Strategic National Initiative
The initiative, known as the "Next-Generation Edge AI Semiconductor Research and Development Program," is promoted by the Japan Science and Technology Agency (JST). Its primary objective is to develop a sophisticated computational infrastructure by merging advanced AI technology with next-generation edge semiconductors. Genome analysis has been identified as one of the program's key application domains, highlighting its importance in modern science.
MZT is participating in the specific research theme titled "Accelerating Edge Intelligence for AI for Science." This theme is led by Principal Investigator Makoto Taiji of RIKEN and involves collaboration with Tohoku University and Keio University. The project exemplifies a powerful public-private partnership designed to accelerate technological innovation from the laboratory to the market.
MZT's Role and the RASEN Accelerator
Within this framework, MZT is tasked with the crucial role of productization and social implementation of the research outcomes. The company will act as the industrial bridge, integrating AI research from its academic partners into its own technology architecture. MZT has set a target of achieving widespread social implementation of these advancements by 2029.
At the heart of MZT's contribution is its proprietary genome-analysis accelerator, RASEN, which is built on a purpose-designed ASIC architecture. Since its founding in 2020, the company has focused on this specialized hardware approach to overcome computational bottlenecks in genomics. This technology forms the foundation for its role in the national program, building on successful validation with university partners.
The performance of RASEN is a key differentiator, enabling whole-genome sequencing analysis in approximately five minutes on a standard workstation. This capability eliminates the need for costly supercomputers or high-performance computing clusters typically required for such tasks. Independent validation with Tohoku University confirmed a 99.8% concordance rate with conventional methods, ensuring its high speed does not sacrifice accuracy.
Vision for Commercialization and Impact
Keisuke Harashima, President and CEO of MZT, expressed that this participation is a tremendous honor and a pivotal moment for the company. He noted that RASEN is at an inflection point, ready to transition from a research concept to a real-world deployment. Harashima affirmed the company will leverage this opportunity to accelerate its commercialization efforts across key sectors.
The company is targeting broad applications for its accelerated genome analysis technology in fields such as healthcare, drug discovery, and scientific research infrastructure. By delivering transformative speed improvements, MZT aims to contribute to solving global challenges in medicine, food security, and energy. This initiative aligns perfectly with the company's mission to harness cutting-edge chip technology for societal benefit.
MZT's integration into this prestigious national program represents a significant milestone for the company and Japan's broader deep-tech ecosystem. The collaboration between MZT, RIKEN, and leading universities is poised to fast-track the development of next-generation AI and semiconductor technologies. Ultimately, this partnership promises to unlock new possibilities in personalized medicine and data-intensive scientific discovery by making rapid genome analysis more accessible.